Oxford Science Enterprises
Venture capital firm based in Oxford, UK
Latest Oxford Science Enterprises investments
Oxford Science Enterprises has invested in these startups.
Scripta Therapeutics
Scripta secures £9.1m seed to reprogramme transcription networks for Alzheimer’s. Read more
Valink Therapeutics
Cambridge based Valink Therapeutics closes £8.8m led by Redalpine with LongeVC. Valink Therapeutics's discovery platform combines dual targeting and precise drug delivery to improve cancer treatment outcomes. Read more
Wild Bioscience
Biotech startup Wild Bioscience raises £45m led by EIT with Oxford Science Enterprises. Wild Bioscience's crop improvement platform combines AI models and precision breeding to improve crop yields and climate resilience. Read more
Kneu Health
Kneu Health raises £4.18m led by Oxford Science Enterprises and Cedars Sinai. Kneu Health's precision neurology platform combines AI models and smartphone monitoring to speed up access to treatment. Read more
Ultromics
Ultromics secures £41.4 million to advance AI-driven heart disease diagnostics, harnessing tech to transform patient care. Read more
Alloyed
Alloyed secures £37M in funding to enhance metal manufacturing, expanding facilities in the UK and USA for groundbreaking tech advancements. Read more
Neu Health
New partnership ignites health-tech startup growth, launching innovative solutions for Parkinson's and dementia in the UK and US. Read more
Fractile
Fractile secures $15M in Seed funding for groundbreaking AI chip, poised to revolutionize the industry with cutting-edge technology. Read more
Oxford Endovascular
Oxford Endovascular secures GBP8m in funding to revolutionize treatment for brain aneurysms, bringing life-saving device closer to market. Read more
Investments By Sector
Oxford Science Enterprises has invested in these sectors
| AI | 36.4% |
| Healthtech | 27.3% |
| Biotech | 27.3% |
| Tech | 9.1% |
